Compare · CF vs EVGN
CF vs EVGN
Side-by-side comparison of CF Industries Holdings Inc. (CF) and Evogene Ltd (EVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CF and EVGN operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CF is the larger of the two at $18.13B, about 2868.5x EVGN ($6.3M).
- EVGN has been more active in the news (11 items in the past 4 weeks vs 3 for CF).
- CF has more recent analyst coverage (25 ratings vs 4 for EVGN).
- Company
- CF Industries Holdings Inc.
- Evogene Ltd
- Price
- -
- -
- Market cap
- $18.13B
- $6.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2005
- News (4w)
- 3
- 11
- Recent ratings
- 25
- 4
CF Industries Holdings Inc.
CF Industries Holdings, Inc. manufactures and sells hydrogen and nitrogen products for clean energy, fertilizer, emissions abatement, and other industrial applications worldwide. Its principal products include anhydrous ammonia, granular urea, urea ammonium nitrate, and ammonium nitrate products. The company also offers diesel exhaust fluid, urea liquor, nitric acid, and aqua ammonia products; and compound fertilizer products with nitrogen, phosphorus, and potassium. It primarily serves cooperatives, independent fertilizer distributors, traders, wholesalers, and industrial users. The company was founded in 1946 and is headquartered in Deerfield, Illinois.
Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Latest CF
- CF Industries Holdings, Inc. Declares Quarterly Dividend and Confirms Dates for Third Quarter 2026 Results and Conference Call
- CF Industries upgraded by Rothschild & Co Redburn with a new price target
- Bernstein initiated coverage on CF Industries with a new price target
- SEC Form 8-K filed by CF Industries Holdings Inc.
- CF Industries, JERA Co., and Mitsui & Co., Ltd., Break Ground on Blue Point One, the World’s Largest Low-Carbon Ammonia Plant in Louisiana
- SEC Form SCHEDULE 13G filed by CF Industries Holdings Inc.
- SEC Form 10-Q filed by CF Industries Holdings Inc.
- CF Industries Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CF Industries Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CF Industries Holdings, Inc. Reports First Half 2026 Net Earnings of $1.34 Billion, Adjusted EBITDA of $2.18 Billion
Latest EVGN
- SEC Form 6-K filed by Evogene Ltd
- Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
- SEC Form 4 filed by Director Recanati Leon
- SEC Form 4 filed by Director Nimrodi Nir
- SEC Form 4 filed by Director Percy Adrian John
- SEC Form 4 filed by Director Falk Dan Michael
- SEC Form 6-K filed by Evogene Ltd
- Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
- SEC Form EFFECT filed by Evogene Ltd
- SEC Form 6-K filed by Evogene Ltd